Silence Therapeutics

Silence Therapeutics logo

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

Contact Silence Therapeutics via their website

News archive

19/05/2021   Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study...more
22/02/2021   Silence Therapeutics to Participate in March Investor Conferences...more
17/02/2021   Silence Therapeutics Initiates Dosing in SLN360 Phase 1 Clinical Trial...more
05/02/2021   Silence Therapeutics plc Announces $45 Million Private Placement...more
06/01/2021   Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer...more
06/01/2021   Michael H. Davidson MD joins Silence Therapeutics as a Non-Executive Director ...more

16/11/2020   Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 ...more
02/11/2020   Silence Therapeutics Appoints new Senior VP, Molecular Design...more
14/09/2020   Silence Therapeutics Appoints Mark Rothera as President and CEO...more
08/09/2020   Silence Therapeutics announces completion of NASDAQ listing...more
21/08/2020   Silence Therapeutics Publicly Files NASDAQ Registration Statement...more
16/07/2020   Silence Therapeutics Announces Mallinckrodt Exercise of Options...more
25/03/2020   Silence Therapeutics Announces Collaboration with AstraZeneca...more
17/02/2020   Silence Therapeutics Launches Scientific Advisory Board...more

24/09/2019   Silence Therapeutics triggers first milestone for SLN500 in Mallinckrodt collaboration...more
05/08/2019   Silence Therapeutics appoints Jørgen Wittendorff as Head of Manufacturing...more
29/07/2019   Silence Therapeutics appoints Dr Steven Romano as Non-Executive Director...more
18/07/2019   Mallinckrodt to make equity investment in Silence Therapeutics...more
28/05/2019   Silence Therapeutics announces collaboration with Genomics England...more
18/04/2019   Silence Therapeutics Appoints New Chief Financial Officer and New Chief Medical Officer...more
27/03/2019   Silence Therapeutics submits Clinical Trial Application for SLN124...more
11/03/2019   Silence Therapeutics preliminary results demonstrate transformational change...more
15/01/2019   Silence Therapeutics Announces Orphan Drug Designation by EMA for SLN124...more

20/08/2018   Silence Therapeutics Announces Board Change...more
17/07/2018   Silence Therapeutics plc Appoints David Horn Solomon as Chief Executive Officer...more
11/07/2018   Silence Therapeutics joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code